BIO Stock Analysis: Bio-Rad Laboratories | NYSE
Medical Devices | NYSE, USA | Market Cap: 7.899m USD | 12M Return: 13.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.0M
EPS Trend: -94.1%
Qual. Beats: 0
Rev. Trend: -75.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bio-Rad Laboratories, Inc. is a global manufacturer and distributor of life science research and clinical diagnostic products, operating through two main segments: Life Science and Clinical Diagnostics. The Life Science segment supplies instruments, reagents, and consumables used to separate, purify, and analyze biological materials such as cells, proteins, and nucleic acids, serving universities, government agencies, pharmaceutical and biotechnology companies, and food safety laboratories. The Clinical Diagnostics segment produces diagnostic test systems, test kits, informatics software, and quality controls for clinical, hospital, reference, and transfusion laboratories. The company sells its products through both a direct commercial organization and third-party distributors and resellers across the United States, Europe, Asia, Canada, and Latin America.
Founded in 1952 and headquartered in Hercules, California, Bio-Rad is classified within the Health Care sector and the Life Sciences Tools & Services sub-industry. The companys dual-segment model combines recurring revenue from clinical diagnostics consumables with longer-cycle capital equipment and reagents sales to research and biopharmaceutical customers, giving it exposure to both healthcare delivery and broader life sciences research spending.
- Sartorius stake value swings amplify Bio-Rad quarterly earnings volatility
- Clinical Diagnostics revenue normalizes after COVID testing windfall
- Life Science segment pressured by biotech R&D budget cuts and FX headwinds
| Net Income: 168.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.16 > 1.0 |
| NWC/Revenue: 78.19% < 20% (prev 99.56%; Δ -21.37% < -1%) |
| CFO/TA 0.05 > 3% & CFO 510.4m > Net Income 168.8m |
| Net Debt (-11.7m) to EBITDA (469.7m): -0.02 < 3 |
| Current Ratio: 3.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.0m) vs 12m ago -3.57% < -2% |
| Gross Margin: 51.87% > 18% (prev 53.50%; Δ -1.64% > 0.5%) |
| Asset Turnover: 26.81% > 50% (prev 26.67%; Δ 0.14% > 0%) |
| Interest Coverage Ratio: 5.51 > 6 (EBIT TTM 271.6m / Interest Expense TTM 49.3m) |
| A: 0.21 (Total Current Assets 2.94b - Total Current Liabilities 917.0m) / Total Assets 9.79b |
| B: 0.78 (Retained Earnings 7.65b / Total Assets 9.79b) |
| C: 0.03 (EBIT TTM 271.6m / Avg Total Assets 9.66b) |
| D: 2.33 (Book Value of Equity 6.85b / Total Liabilities 2.94b) |
| Altman-Z'' = 6.54 = AAA |
| DSRI: 0.98 (Receivables 426.2m/424.7m, Revenue 2.59b/2.54b) |
| GMI: 1.03 (GM 53.50% / 51.87%) |
| AQI: 1.03 (AQ_t 0.63 / AQ_t-1 0.61) |
| SGI: 1.02 (Revenue 2.59b / 2.54b) |
| TATA: -0.03 (NI 168.8m - CFO 510.4m) / TA 9.79b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 296.11 with a total of 144,441 shares traded. Over the past week, the price has changed by -0.25%, over one month by +1.75%, over three months by +6.04% and over the past year by +13.94%.
Current recommended Stop Loss: 283.60 (which is 4.2% or 1.2 ATR below the current price).
Bio-Rad Laboratories has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BIO.
- StrongBuy: 2
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 297 | 0.3% |
P/E Trailing = 49.1917
P/E Forward = 33.557
P/S = 3.0498
P/B = 1.1596
P/EG = 1.1905
Revenue TTM = 2.59b USD
EBIT TTM = 271.6m USD
EBITDA TTM = 469.7m USD
Long Term Debt = 802.9m USD (from longTermDebt, last quarter)
Short Term Debt = 436.7m USD (from shortTermDebt, last quarter)
Debt = 1.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 174.8m
Net Debt = -11.7m USD (calculated: Debt 1.55b - CCE 1.56b)
Enterprise Value = 7.89b USD (7.90b + Debt 1.55b - CCE 1.56b)
Interest Coverage Ratio = 5.51 (Ebit TTM 271.6m / Interest Expense TTM 49.3m)
EV/FCF = 22.08x (Enterprise Value 7.89b / FCF TTM 357.2m)
FCF Yield = 4.53% (FCF TTM 357.2m / Enterprise Value 7.89b)
FCF Margin = 13.79% (FCF TTM 357.2m / Revenue TTM 2.59b)
Net Margin = 6.52% (Net Income TTM 168.8m / Revenue TTM 2.59b)
Gross Margin = 51.87% ((Revenue TTM 2.59b - Cost of Revenue TTM 1.25b) / Revenue TTM)
Gross Margin QoQ = 52.25% (prev 49.80%)
Tobins Q-Ratio = 0.81 (Enterprise Value 7.89b / Total Assets 9.79b)
Interest Expense / Debt = 3.17% (Interest Expense 49.3m / Debt 1.55b)
Taxrate = 24.07% (53.5m / 222.3m)
NOPAT = 206.2m (EBIT 271.6m * (1 - 24.07%))
Current Ratio = 3.21 (Total Current Assets 2.94b / Total Current Liabilities 917.0m)
Debt / Equity = 0.23 (Debt 1.55b / totalStockholderEquity, last quarter 6.85b)
Debt / EBITDA = -0.02 (Net Debt -11.7m / EBITDA 469.7m)
Debt / FCF = -0.03 (Net Debt -11.7m / FCF TTM 357.2m)
Total Stockholder Equity = 7.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.75% (Net Income 168.8m / Total Assets 9.79b)
RoE = 2.40% (Net Income TTM 168.8m / Total Stockholder Equity 7.04b)
RoCE = 3.46% (EBIT 271.6m / Capital Employed (Equity 7.04b + L.T.Debt 802.9m))
RoIC = 2.25% (NOPAT 206.2m / Invested Capital 9.18b)
WACC = 7.53% (E(7.90b)/V(9.45b) * Re(8.54%) + D(1.55b)/V(9.45b) * Rd(3.17%) * (1-Tc(0.24)))
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.67 | Cagr: -2.92%
[DCF] Terminal Value 76.38% ; FCFF base≈347.2m ; Y1≈370.4m ; Y5≈443.1m
[DCF] Fair Price = 314.2 (EV 6.81b - Net Debt -11.7m = Equity 6.82b / Shares 21.7m; r=8.35% [WACC [floored]]; 5y FCF grow 7.56% → 2.50% )
EPS Correlation: -94.08 | EPS CAGR: -8.18% | SUE: -0.22 | # QB: 0
Revenue Correlation: -75.26 | Revenue CAGR: -2.26% | SUE: 0.20 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.75 | Chg30d=-28.74% | Revisions=-40% | Analysts=3
EPS next Quarter (2026-09-30): EPS=2.31 | Chg30d=-14.93% | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=9.00 | Chg30d=-12.26% | Revisions=-57% | GrowthEPS=-9.2% | GrowthRev=-0.6%
EPS next Year (2027-12-31): EPS=9.72 | Chg30d=-14.33% | Revisions=-57% | GrowthEPS=+8.0% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: -80% (up=0, down=12)